Quantcast

Latest Novartis Group Stories

2009-12-08 08:15:00

EAST HANOVER, N.J., Dec. 8 /PRNewswire/ -- In a large Phase III clinical trial, Tasigna® (nilotinib) 200 mg capsules demonstrated greater efficacy over Gleevec® (imatinib mesylate) tablets* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase(1). To view the multimedia assets associated with this release, please click:...

2009-11-12 00:45:00

BASEL, Switzerland, Nov. 12 /PRNewswire/ -- Novartis announced the availability of Prevacid®24HR (lansoprazole delayed-release capsules 15 mg/acid reducer) over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn. Prevacid®24HR received US Food and Drug Administration (FDA) approval in May 2009. It is the first and only over-the-counter (OTC) Proton Pump Inhibitor (PPI) for the treatment of frequent heartburn in its...

2009-10-20 00:15:00

EAST HANOVER, N.J., Oct. 20 /PRNewswire/ -- Novartis announced today that Tasigna® (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec® (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)...

2009-10-12 17:01:00

EAST HANOVER, N.J., Oct. 12 /PRNewswire-FirstCall/ -- Novartis Pharma AG has entered into an agreement for exclusive US and Canadian rights to Fanapt(TM) (iloperidone), a new oral medication that is approved by the US Food and Drug Administration (FDA) for the acute treatment of adults with schizophrenia. Novartis plans to launch Fanapt in the US in early 2010. As part of the agreement with Vanda Pharmaceuticals Inc., Novartis will have exclusive commercialization rights to the...

2009-10-01 06:30:00

EAST HANOVER, N.J., Oct. 1 /PRNewswire/ -- Data published in the Journal of Clinical Oncology show that patients with advanced neuroendocrine tumors (NET) of the midgut who were treated with Sandostatin® LAR( )Depot (octreotide acetate for injectable suspension) experienced a 66% reduction in risk of disease progression versus placebo(1). Sandostatin LAR is indicated to treat the diarrhea and flushing episodes associated with advanced carcinoid tumors(2). To view...

2009-09-17 15:05:00

EAST HANOVER, N.J., Sept. 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Valturna((R)) (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure. This is the first approval for Valturna, which is indicated for the treatment of high blood pressure in patients not adequately controlled on aliskiren or...

2009-09-17 15:05:00

EAST HANOVER, N.J., Sept. 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Valturna(R) (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure. This is the first approval for Valturna, which is indicated for the treatment of high blood pressure in patients not adequately controlled on aliskiren or...

2009-08-19 16:13:00

EAST HANOVER, N.J., Aug. 19 /PRNewswire/ -- Newly published data in The New England Journal of Medicine affirm five-year upfront use of Femara((R)) (letrozole tablets) following surgery as an optimal treatment approach versus tamoxifen for postmenopausal women with early stage breast cancer (hormone-receptor positive). The data include an analysis from the Breast International Group (BIG) 1-98 trial that evaluated patients taking either a sequence of Femara and tamoxifen for five years...

2009-08-17 00:15:00

EAST HANOVER, N.J., Aug. 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease. Extavia is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS...

2009-06-08 00:24:00

- Afinitor significantly reduced tumor size by 50% or more in one out of three patients with refractory or relapsed lymphoma - Phase III study underway to explore potential of Afinitor to prevent relapse in patients with the most common type of non-Hodgkin's lymphoma EAST HANOVER, N.J., June 8 /PRNewswire/ -- New data show that Afinitor(R) (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin's lymphoma (NHL) and Hodgkin's disease(1). Based on...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related